CCR5 and Hepatic fibrosis: The administration of a combination of a CCR2/ C-C chemokine receptor type 5 (CCR5) inhibitor and a fibroblast growth factor 21 analogue reduces the recruitment of these macrophages and liver fibrosis in a murine model of NASH [22].